Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.

ABSTRACT:

Aims

To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme.

Materials and methods

The SUSTAIN clinical trial programme evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1 analogue, for the treatment of type 2 diabetes (T2D). In SUSTAIN 6, a 2-year, pre-approval cardiovascular outcomes trial, semaglutide was associated with a significant increase in the risk of DR complications (DRC) vs placebo. DR data from across the SUSTAIN trials were evaluated, and post hoc analyses of the SUSTAIN 6 data were conducted. These included subgroup analyses to identify at-risk patients and a mediation analysis with initial change in glycated haemoglobin (HbA1c; percentage-points at week 16) as a covariate, to examine the role of th

SUBMITTER: Vilsboll T 

PROVIDER: S-EPMC5888154 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature